logo
Cantonment man finds rare meteorite after fireball

Cantonment man finds rare meteorite after fireball

Yahoo4 days ago
It was the darkened morning hours of July 6 when Christian Varady saw the fireball falling from the sky, a momentary streak of fiery light that appeared above his Cantonment home without a sound.
"To me it seemed about this big," Varady said, positioning his hands as if holding an invisible basketball. "It was green and yellowish and then changed to blue and yellowish. It seemed like it lasted about five seconds, but it was probably just two seconds or so."
He knew it landed close by. The streak seemed to hit near a well-manicured yard across the street, just a house down.
When daylight came, Varady took his dog for a walk and thought he might do a little searching for evidence of what he saw hours earlier. He talked to the neighbor with the lush, green lawn and asked permission to search in his yard near the street. The man said sure, and Varady looked and soon found a pock mark in the grass, a small area of disturbance just a few inches across and a few inches deep.
Inside, was a small rock-sized, rock-shaped something. He wasn't sure what the small piece was, but he had a guess.
It was a meteorite.
He searched around online hoping to find someone to help him confirm what he found, and everything led him to Wayne Wooten, the noted Pensacola astronomer and longtime astronomy professor at Pensacola State College with a doctorate degree in astronomy from the University of Florida.
The two met at a Whataburger and Wooten observed the small piece.
His take?
"It's a meteorite," Wooten said on a recent visit to Varady's home, where he brought out his own kit of collected meteorites to compare with the new find. "I don't know anything else it could be."
Of course, Varady would have to have the space rock chemically analyzed to make a 100% confirmation, but Wooten seems convinced, already matching the rock's probable makeup, which he estimates to be about 10% iron along with a mixture of silicate stone, with another meteorite from Northwest Africa found in the early 2000s.
"We have something really cool here," Wooten said as he examined Varady's find. "Very rare."
That's because, truly, it wasn't a "find." It was a "fall."
In meteoritics − the study of meteors and meteorites − a "find" is fairly common and involves someone just finding a meteorite.
A "fall" is much rarer and occurs when someone spots a falling meteorite, then finds it.
According to the Meteoritical Bulletin Database, less than 500 "falls" have been recorded worldwide since 1950.
Finds happen when folks discover meteorites that could have been on earth for thousands of years, while falls are always fresh meteorites. (A meteor is the falling space object, while a meteorite is a piece that actually reaches earth without burning up from the heat generated when entering the Earth's atmosphere.)
Meet Wayne Wooten: Legendary astronomy professor stepping down because of Parkinson's
Wooten guesses that Varady's meteorite survived because it was traveling relatively slow and because of its small size − remember that he didn't hear a sonic boom.
"It's a good match for a chondrite meteorite, which is the most common," Wooten said, while watching Varady pick up his meteorite with a small magnet. "This one is very weakly magnetic. If he sneezes, it falls. It's probably 10% iron at most."
The meteorites origin?
"It's a chip off the old block," said Wooten, who is the Facebook page moderator for the Escambia Amateur Astronomers Association. "It's from a stony asteroid."
Wooten said it came from an asteroid in the asteroid belt located between Mars and Jupiter, where the large objects are frequently colliding, sending off pieces, many which are "swallowed up by Jupiter" or might even be burned up by the sun. This one got into a near-Earth orbit and could have been circling the planet for hundreds or thousands of years before falling in Cantonment. (Wooten said there are reports that it might have been witnessed as far away as Gulf Shores, Alabama.)
"You saw it coming and you picked it up," Wooten said to Varady, who moved with his family to Cantonment after he lost everything during Hurricane Katrina 20 years ago. "It's one in a million for that to happen. It's just so rare."
Though thousands of meteorites hit the Earth each year, most hit oceans or uninhabited forest areas and are not located. In fact, there is a heavily wooded area surrounding Varady's Cantonment subdivision.
One of the most celebrated meteorite finds in Northwest Florida came in 1983 when treasure hunters using metal detectors found a bowling ball-sized meteorite in Grayton Beach, which is still one of the largest meteorites found in the Southeastern United States.
But that was a "find" and not the rare "fall" discovery.
"That's what makes Christian's so unique,'' Wooten said. "He saw that sucker coming in."
Varady now hopes that some lab will take interest in his find and conduct official scientific testing.
This article originally appeared on Pensacola News Journal: Meteorite found in Cantonment after man watches it fall from sky
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

What causes Parkinson's disease? Scientists uncover an unexpected new clue.
What causes Parkinson's disease? Scientists uncover an unexpected new clue.

National Geographic

time2 hours ago

  • National Geographic

What causes Parkinson's disease? Scientists uncover an unexpected new clue.

A computer illustration of human pegivirus, an RNA (ribonucleic acid) virus scientists believe may be linked to Parkinson's disease. Illustration by Kateryna Kon, Science Photo Library A recent study linking human pegivirus to Parkinson's is leading scientists to examine the connection between other viral infections and neurodegenerative diseases. More than 10 million people worldwide are living with Parkinson's disease, a progressive neurodegenerative disorder that leads to symptoms such as tremors, slow movement, limb stiffness, and balance issues. Scientists still don't know what causes the disease, but it's thought to develop due to a complex mixture of genetic and environmental factors, and treatment is still quite limited. But new research is putting scientists one step closer to some possible answers. In a recent study published in JCI Insight, researchers found a common virus, called human pegivirus (HPgV), in the brains of patients who had Parkinson's disease when they died. Although HPgV infections don't usually cause symptoms, researchers believe the virus may be playing a role in the development of Parkinson's. 'The hypothesis is that a long-term, low-burning infection might lead to these sorts of diseases,' such as Parkinson's disease and other neurodegenerative disorders, says Barbara Hanson, a researcher at Northwestern University Feinberg School of Medicine, and one of the authors of the paper. Here's what we know so far. Colored Magnetic Resonance Imaging (MRI) scan showing the brain of a 65-year-old patient with Parkinson's. New research suggests that viral infections can be at play in the development of the disease. Photograph by Zephyr/Science Photo Library Over 500 viruses screened In this study, researchers screened for over 500 viruses in the autopsied brains of 10 patients who had Parkinson's disease and compared them to the autopsied brains of 14 control patients, who were matched for age and gender. In five of the patients with Parkinson's, they found the presence of HPgV, while none of the control patients had the virus. In order to bolster their findings, researchers conducted follow-up experiments that looked at the blood samples of patients who were in different stages of Parkinson's disease. What they found was that patients who had Parkinson's and were positive for HPgV had similar immune system responses, including a lower level of an inflammatory protein called IL-4, which can either promote or suppress inflammation depending on the situation. They also found that patients who had a specific Parkinson's-related gene mutation had a different immune system response to HPgV, compared to patients with Parkinson's who didn't have the mutation. 'It was a very thorough study,' says Margaret Ferris, a neurologist and researcher at Stanford University who was not part of the study. She adds that this offers a possible mechanism for the interaction between genetics and environment. Although the presence of HPgV in the brains of people with Parkinson's disease is suggestive of a link, the full answer of what causes the neurodegenerative disease is more complex. Parkinson's disease has always been hard to study, due to the fact that it develops slowly, over many years, and is difficult to diagnose in the earlier stages. 'One of the hard things about investigating neurodegenerative disorders is that it is very hard to identify people who will get neurodegenerative disorders, but don't yet have them, and to study and watch them,' Ferris says. Further complicating this matter is the fact that there doesn't seem to be one single trigger for Parkinson's disease. 'It is difficult to determine the causes of Parkinson's, because they are likely multifactorial,' says William Ondo, a neurologist at Houston Methodist Hospital, who specializes in treating patients with movement disorders such as Parkinson's disease. Ondo was not part of the study. Currently, Parkinson's disease is believed to develop from a complex mixture of genetic and environmental factors, with individual triggers varying from one person to another. This makes studying the potential causes of the disease quite challenging, and means that there still aren't definitive answers to what can trigger the condition. It's likely that some people may develop Parkinson's disease as a result of multiple triggers. 'Everyone is on their own path,' to developing Parkinson's disease, says Erin Furr-Stimming, a neurologist at McGovern Medical School at UTHealth Houston, who was not part of the study. In recent years, there has been a growing body of evidence to suggest a link between viral infections and the development of neurological diseases, such as multiple sclerosis, Alzheimer's, and Parkinson's. This includes the recent discovery that Epstein-Barr virus is a major trigger for multiple sclerosis, as well as a number of associations between viral infections and neurodegenerative conditions. Parkinson-like symptoms have also been triggered by a number of viral infections, such as West Nile virus, St. Louis Encephalitis virus, and Japanese Encephalitis B Virus. As Hanson notes, inflammation in the brain has been linked to the development of neurodegenerative disorders, with viral infections being a potential trigger for this inflammation. 'Any amount of inflammation in the brain can trigger a number of cascades that lead to the loss of normal homeostatic brain function,' Hanson says. 'It's possible that viral infections are one of those triggers that lead to inflammation in the brain.' Other potential reasons that viral infections may lead to neurodegeneration include direct damage to neurons from the virus, or the accumulation of misfolded proteins. However, while this recent study offers evidence of a suggested link between HPgV and the development of Parkinson's disease, there's still more research needed before a clear link between the two can be established. 'This study doesn't show a cause-and-effect relationship—it just suggests there may be a relationship between pegivirus and Parkinson's,' says Joseph Jankovic, a neurologist and director of the Parkinson's Disease Center and Movement Disorders Clinic at Baylor College of Medicine. In order to understand the connection further, Jankovic says, 'this study needs to be replicated in a different cohort of patients.'

Biogen plans to invest $2B into its RTP manufacturing facilities
Biogen plans to invest $2B into its RTP manufacturing facilities

Axios

time17 hours ago

  • Axios

Biogen plans to invest $2B into its RTP manufacturing facilities

Biogen, one of the world's largest biotechnology companies, plans to invest $2 billion and build a new manufacturing facility in Research Triangle Park. Why it matters: Biogen is one of RTP's largest employers with more than 1,500 workers in Durham County. The latest investment will help it expand its manufacturing capabilities in North Carolina. Between the lines: Investment into pharmaceutical and biotech manufacturing remains on fire in the Triangle, with Biogen representing just the latest in a string of jobs announcements. The biotechnology company Genentech said earlier this year it plans to add 400 jobs in Holly Springs, and Amgen and Fujifilm Diosynth recently completed manufacturing facilities there as well. Last year, Novo Nordisk, the Danish maker of drugs like Ozempic, announced a planned $4 billion investment in facilities in Johnston County. Zoom in: The investment will help the drug maker build its eighth manufacturing facility in North Carolina, Biogen said in a statement. The company makes a variety of treatments, including for multiple sclerosis, and has a pipeline of products being tested for Alzheimer's, Parkinson's and other diseases. The company declined an interview request, and it was unclear how many jobs could be supported at the new facility. In 2023, the company laid off some workers due to the bumpy launch of an Alzheimer's treatment, Fierce Biotech reported. The big picture: The Triangle, which the real estate services firm JLL pegs as the fourth-largest life sciences market in the country, has a lower vacancy rate than its larger peers for life science space. That's primarily due to a combination of the region not building as much as markets like Boston and San Diego since the pandemic, plus a number of biomanufacturing wins, according to Eric Forshee, JLL's executive vice president for life sciences at its Raleigh office. "North Carolina, especially on the biomanufacturing side, has good affordable land, quality sites, great talent and good incentives," Forshee told Axios. What's next: Reuters noted that Biogen is one of several drug makers that have announced investments amid the threat of a 200% tariff on imported drugs from the Trump administration, though Biogen's announcement made no mention of tariffs. It remains to be seen how tariffs could help or hinder biomanufacturing in the Triangle.

The brain tech revolution is here — and it isn't all Black Mirror
The brain tech revolution is here — and it isn't all Black Mirror

Vox

time3 days ago

  • Vox

The brain tech revolution is here — and it isn't all Black Mirror

is a senior editorial director at Vox overseeing the climate teams and the Unexplainable and The Gray Area podcasts. He is also the editor of Vox's Future Perfect section and writes the Good News newsletter. He worked at Time magazine for 15 years as a foreign correspondent in Asia, a climate writer, and an international editor, and he wrote a book on existential risk. When you hear the word 'neurotechnology,' you may picture Black Mirror headsets prying open the last private place we have — our own skulls — or the cyber-samurai of William Gibson's Neuromancer. That dread is natural, but it can blind us to the real potential being realized in neurotech to address the long intractable medical challenges found in our brains. In just the past 18 months, brain tech has cleared three hurdles at once: smarter algorithms, shrunken hardware, and — most important — proof that people can feel the difference in their bodies and their moods. A pacemaker for the brain Keith Krehbiel has battled Parkinson's disease for nearly a quarter-century. By 2020, as Nature recently reported, the tremors were winning — until neurosurgeons slipped Medtronic's Percept device into his head. Unlike older deep-brain stimulators that carpet-bomb movement control regions in the brain with steady current, the Percept listens first. It hunts the beta-wave 'bursts' in the brain that mark a Parkinson's flare and then fires back millisecond by millisecond, an adaptive approach that mimics the way a cardiac pacemaker paces an arrhythmic heart. In the ADAPT-PD study, patients like Krehbiel moved more smoothly, took fewer pills, and overwhelmingly preferred the adaptive mode to the regular one. Regulators on both sides of the Atlantic agreed: The system now has US and EU clearance. Because the electrodes spark only when symptoms do, total energy use is reduced, increasing battery life and delaying the next skull-opening surgery. Better yet, because every Percept shipped since 2020 already has the sensing chip, the adaptive mode can be activated with a simple firmware push, the way you'd update your iPhone. Waking quiet muscles Scientists applied the same listen-then-zap logic farther down the spinal cord this year. In a Nature Medicine pilot, researchers in Pittsburgh laid two slender electrode strips over the sensory roots of the lumbar spine in three adults with spinal muscular atrophy. Gentle pulses 'reawakened' half-dormant motor neurons: Every participant walked farther, tired less, and — astonishingly — one person strode from home to the lab without resting. Half a world away, surgeons at Nankai University threaded a 50-micron-thick 'stent-electrode' through a patient's jugular vein, fanned it against the motor cortex, and paired it with a sleeve that twitched his arm muscles. No craniotomy, no ICU — just a quick catheter procedure that let a stroke survivor lift objects and move a cursor. High-tech rehab is inching toward outpatient care. Mental-health care on your couch The brain isn't only wires and muscles; mood lives there, too. In March, the Food and Drug Administration tagged a visor-like headset from Pulvinar Neuro as a Breakthrough Device for major-depressive disorder. The unit drips alternating and direct currents while an onboard algorithm reads brain rhythms on the fly, and clinicians can tweak the recipe over the cloud. The technology offers a ray of hope for patients whose depression has resisted conventional treatments like drugs. Thought cursors and synthetic voices Cochlear implants for people with hearing loss once sounded like sci-fi; today more than 1 million people hear through them. That proof-of-scale has emboldened a new wave of brain-computer interfaces, including from Elon Musk's startup Neuralink. The company's first user, 30-year-old quadriplegic Noland Arbaugh, told Wired last year he now 'multitasks constantly' with a thought-controlled cursor, clawing back some of the independence lost to a 2016 spinal-cord injury. Neuralink isn't as far along as Musk often claims — Arbaugh's device experienced some problems, with some threads detaching from the brain — but the promise is there. On the speech front, new systems are decoding neural signals into text on a computer screen, or even synthesized voice. In 2023 researchers from Stanford and the University of California San Francisco installed brain implants in two women who had lost the ability to speak, and managing to hit decoding times of 62 and 78 words per minute, far faster than previous brain tech interfaces. That's still much slower than the 160 words per minute of natural English speech, but more recent advances are getting closer to that rate. Guardrails for gray matter Yes, neurotech has a shadow. Brain signals could reveal a person's mood, maybe even a voting preference. Europe's new AI Act now treats 'neuro-biometric categorization' — technologies that can classify individuals by biometric information, including brain data — as high-risk, demanding transparency and opt-outs, while the US BRAIN Initiative 2.0 is paying for open-source toolkits so anyone can pop the hood on the algorithms. And remember the other risk: doing nothing. Refusing a proven therapy because it feels futuristic is a little like turning down antibiotics in 1925 because a drug that came from mold seemed weird. Twentieth-century medicine tamed the chemistry of the body; 21st-century medicine is learning to tune the electrical symphony inside the skull. When it works, neurotech acts less like a hammer than a tuning fork — nudging each section back on pitch, then stepping aside so the music can play. Real patients are walking farther, talking faster, and, in some cases, simply feeling like themselves again. The challenge now is to keep our fears proportional to the risks — and our imaginations wide enough to see the gains already in hand. A version of this story originally appeared in the Good News newsletter. Sign up here!

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store